This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ratko, T. A. Articles by Moon, R. C. Search for Related Content PubMed PubMed Citation Articles by Ratko, T. A. Articles by Moon, R. C.

Inhibition of Rat Mammary Gland Chemical Carcinogenesis by Dietary Dehydroepiandrosterone or a Fluorinated Analogue of Dehydroepiandrosterone¹

Laboratory of Pathophysiology, Life Sciences Division, IIT Research Institute, Chicago, Illinois 60616 [T. A. R., R. G. M., C. J. D., and R. C. M.], and National Cancer Institute, Chemoprevention Branch, Bethesda, Maryland 20892 [G. J. K.]

The chemopreventive efficacy of p.o. administered dehydroepiandrosterone (DHEA), DHEA plus N-(4-hydroxyphenyl)retinamide (4-HPR), or 16-fluoro-5-androsten-17-one (DHEA analogue 8354) was examined in rats treated with N-methyl-N-nitrosourea (MNU; 50 mg/kg body weight, i.v.) at 50 days of age. Semipurified diet (AIN-76A) containing each steroid alone, or DHEA plus 4-HPR, was administered during initiation (-1 week to +1 week post-MNU), promotion/progression (+1 week post-MNU to termination), or both phases (-1 week post-MNU to termination) of the carcinogenic process. Neither DHEA nor DHEA analogue 8354 (0.2%, w/w) significantly affected the initiation of mammary cancer when administered alone; however, DHEA (0.2%, w/w) plus 4-HPR (1 mmol/kg diet) significantly reduced cancer multiplicity (26%) when given during initiation. All three treatments were strongly effective when given during promotion/progression, significantly reducing mammary cancer multiplicity by 77% (DHEA), 84% (DHEA/4-HPR), and 66% (DHEA analogue 8354), relative to carcinogen controls. Cancer incidence was significantly inhibited by DHEA (33% inhibition) and DHEA/4-HPR (24% reduction) during promotion/progression. However, the most effective chemopreventive treatment encompassed both phases of carcinogenesis. Thus, under these conditions, DHEA (0.2% or 0.1%, w/w) reduced cancer incidence (52% and 32% reductions, respectively) and multiplicity (91% and 86% reductions, respectively). Further reduction in mammary cancer incidence was observed in animals that received DHEA (both doses) plus 4-HPR (1 and 0.5 mmol/kg diet, respectively). DHEA analogue 8354 (0.2% or 0.1%, w/w) given for the duration of the study reduced only cancer multiplicity (61% and 56% reductions, respectively). Tumor-related mortality was significantly lower in rats that received long-term treatment with DHEA or DHEA/4-HPR, when compared with carcinogen controls. Except for a slight, but significant, postcarcinogen decrease in the mean body weights of rats treated concomitantly with DHEA (plus or minus 4-HPR) and MNU, additional gross manifestations of steroid-induced toxicity were not observed.

¹ Supported in part by contract N01-CN-45912-14 and Grant CA-34664 (R. G. M.) from the National Cancer Institute.

² Present address: American Medical Association, 515 North State Street, Chicago, IL 60610.

³ To whom requests for reprints should be addressed, at IIT Research Institute, 10 West 35th Street, Chicago, IL 60616.

Received 3/ 1/90. Accepted 10/24/90.

This article has been cited by other articles:

				F. P. de Heredia, E. Larque, S. Zamora, and M. Garaulet Dehydroepiandrosterone modifies rat fatty acid composition of serum and different adipose tissue depots and lowers serum insulin levels J. Endocrinol., April 1, 2009; 201(1): 67 - 74. [Abstract] [Full Text] [PDF]

				D. L. McCormick, W. D. Johnson, N. M. Kozub, K.V.N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone Carcinogenesis, February 1, 2007; 28(2): 398 - 403. [Abstract] [Full Text] [PDF]

				F Labrie Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr. Relat. Cancer, June 1, 2006; 13(2): 335 - 355. [Abstract] [Full Text] [PDF]

				K. V. N. Rao, W. D. Johnson, M. C. Bosland, R. A. Lubet, V. E. Steele, G. J. Kelloff, and D. L. McCormick Chemoprevention of Rat Prostate Carcinogenesis by Early and Delayed Administration of Dehydroepiandrosterone Cancer Res., July 1, 1999; 59(13): 3084 - 3089. [Abstract] [Full Text] [PDF]

				C. Rodriguez-Burford, R. A. Lubet, I. Eto, M. M. Juliana, G. J. Kelloff, C. J. Grubbs, and V. E. Steele Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model Carcinogenesis, January 1, 1999; 20(1): 71 - 76. [Abstract] [Full Text] [PDF]

				H. D. Danenberg, A. Ben-Yehuda, Z. Zakay-Rones, D. J. Gross, and G. Friedman Dehydroepiandrosterone Treatment Is Not Beneficial to the Immune Response to Influenza in Elderly Subjects J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 2911 - 2914. [Abstract] [Full Text] [PDF]